Transvaginal dehydroepiandrosterone: an unconventional proposal todeliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name

Buster, John E.

doi:10.1097/gme.0b013e3181ae1fca

Cited by 8 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the only precursor of sex hormones for postmenopausal women, the levels of both DHEA and DHEA-S in serum decline with age. It is widely speculated that age-related decline of these C19 steroids might be caused by well-being, deterioration in cognition and lowered libido[ 4 , 5 ], or increased likelihood of low sexual function in both premenopausal and post-menopausal women[ 6 ]. It has been proposed that restoration of serum DHEA in women (60–79 years old) to the level found in young people may have anti-ageing effects[ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Ample Evidence: Dehydroepiandrosterone (DHEA) Conversion into Activated Steroid Hormones Occurs in Adrenal and Ovary in Female Rat

et al. 2015

View full text Add to dashboard Cite

Dehydroepiandrosterone (DHEA) is important for human health, especially for women. All estrogens and practically half of androgens are synthesized from DHEA in peripheral tissues. However, the mechanism and exact target tissues of DHEA biotransformation in the female are not fully clear. The present study showed that maximal content of androstenedione (AD) and testosterone (T) were observed at 3h after DHEA administration in female rats, which was 264% and 8000% above the control, respectively. Estradiol (E2) content significantly increased at 6h after DHEA administration, which was 113% higher than that in control group. Gavage with DHEA could significantly reduce 3β-hydroxysteroid dehydrogenase (3β-HSD) mRNA level at 3-12h and 17β-hydroxysteroid dehydrogenase (17β-HSD) mRNA level at 12h in ovary, while increasing aromatase mRNA levels at 6, 24, and 48h. It is interesting that administration of DHEA caused a significant increase of 17β-HSD, 3β-HSD and aromatase mRNA levels in adrenal. The AD and T contents also markedly increased by 537% and 2737% after DHEA administration in ovariectomised rats, in company with a significant increase in 17β-HSD and 3β-HSD mRNA levels and decreased aromatase mRNA level in adrenal. However, DHEA administration did not restore the decreased E2, estrone (E1), and progesterone (P) caused by the removal of the ovaries in females. These results clearly illustrated that exogenous DHEA is preferentially converted into androgens in adrenal, while its conversion to estrogens mainly happens in the ovary through steroidogenic enzyme in female rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Ample Evidence: Dehydroepiandrosterone (DHEA) Conversion into Activated Steroid Hormones Occurs in Adrenal and Ovary in Female Rat

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Along this line, new information supports that DHEA (dehydroepiandrosterone) was able to decrease vaginal dryness, without evidence of it increasing systemic estrogen and/or testosterone concentrations (22)(23)(24)(25). Further information with regard to the utility of this therapy in breast cancer survivors would be of value.…”

Section: Discussionmentioning

confidence: 85%

A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

Loprinzi¹,

Balcueva²,

Liu³

et al. 2010

JCO

View full text Add to dashboard Cite

Purpose-Vaginal dryness is a common problem, for which effective and safe non-estrogenic treatments are needed. Based on preliminary promising data that pilocarpine attenuated vaginal dryness, the current trial was conducted.Methods-A double-blind, placebo-controlled, randomized trial design was used to compare pilocarpine, at target doses of 5 mg twice daily and 5 mg four times daily, to a placebo. Vaginal dryness was recorded by patient-completed questionnaires at baseline and weekly for 6 weeks after study initiation. The primary endpoint for this study was the area under the curve (AUC) summary statistic comprised of the longitudinal responses obtained at baseline and through the six weeks of treatment to a numerical analogue scale asking patients to rate their perceived amount of vaginal dryness. The primary analysis was carried out by a single t-test using a two-sided Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Results-A total of 201 patients enrolled in this trial. The primary analysis, comparing vaginal dryness symptoms in the collective pilocarpine arms against the placebo arm, did not reveal any benefit for the pilocarpine treatment. This finding was confirmed by other secondary analyses. Toxicity evaluation revealed more nausea, sweating, rigors, and urinary frequency with the pilocarpine arms compared to the placebo arm. NIH Public AccessConclusion-Pilocarpine did not alleviate vaginal dryness.

show abstract

“…Along this line, new information supports that DHEA (dehydroepiandrosterone) was able to decrease vaginal dryness, without evidence of it increasing systemic estrogen and/or testosterone concentrations (22–25). Further information with regard to the utility of this therapy in breast cancer survivors would be of value.…”

Section: Discussionmentioning

confidence: 95%

A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA

Loprinzi¹,

Balcueva²,

Liu³

et al. 2011

The Journal of Supportive Oncology

View full text Add to dashboard Cite

Purpose Vaginal dryness is a common problem, for which effective and safe non-estrogenic treatments are needed. Based on preliminary promising data that pilocarpine attenuated vaginal dryness, the current trial was conducted. Methods A double-blind, placebo-controlled, randomized trial design was used to compare pilocarpine, at target doses of 5 mg twice daily and 5 mg four times daily, to a placebo. Vaginal dryness was recorded by patient-completed questionnaires at baseline and weekly for 6 weeks after study initiation. The primary endpoint for this study was the area under the curve (AUC) summary statistic comprised of the longitudinal responses obtained at baseline and through the six weeks of treatment to a numerical analogue scale asking patients to rate their perceived amount of vaginal dryness. The primary analysis was carried out by a single t-test using a two-sided alternative to compare the collective pilocarpine treatment arms versus the collective placebo arms. Results A total of 201 patients enrolled in this trial. The primary analysis, comparing vaginal dryness symptoms in the collective pilocarpine arms against the placebo arm, did not reveal any benefit for the pilocarpine treatment. This finding was confirmed by other secondary analyses. Toxicity evaluation revealed more nausea, sweating, rigors, and urinary frequency with the pilocarpine arms compared to the placebo arm. Conclusion Pilocarpine did not alleviate vaginal dryness.

show abstract

Transvaginal dehydroepiandrosterone: an unconventional proposal todeliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name

Cited by 8 publications

References 9 publications

Ample Evidence: Dehydroepiandrosterone (DHEA) Conversion into Activated Steroid Hormones Occurs in Adrenal and Ovary in Female Rat

Ample Evidence: Dehydroepiandrosterone (DHEA) Conversion into Activated Steroid Hormones Occurs in Adrenal and Ovary in Female Rat

A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA

Contact Info

Product

Resources

About